SCHEMBL1891742

SCHEMBL1891742

Cc1nc(-c2ccc3c(c2)OCO3)c(N)c(-c2ccc(C(F)(F)F)cc2F)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.48
CLK1 P49759 2/20 0.43
DYRK1A Q13627 2/20 0.43
DYRK1B Q9Y463 2/20 0.43
DYRK2 Q92630 1/20 0.43
ADORA1 P30542 7/20 0.41
ADORA2A P29274 5/20 0.41
ADORA2B P29275 1/20 0.41
ADORA3 P0DMS8 1/20 0.40
DPP4 P27487 1/20 0.40
CLK2 P49760 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
MPL P40238 1/20 0.39
PTGS1 P23219 2/20 0.38
PTGS2 P35354 2/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2390447 0.83 ALDH1A1 (0.39) MAP2K4CLK1DYRK1ADYRK1BDYRK2
SCHEMBL1893971 0.80 FEN1 (0.44) MAP2K4ADORA1ADORA2AMPLKMT2A
SCHEMBL1885446 0.78 MEN1 (0.47) ADORA2AKDM4EMPLKMT2AALOX5AP
SCHEMBL1894636 0.76 CTSA (0.45) ADORA1ADORA2AMPLPTGS1PTGS2
SCHEMBL1891905 0.74 HSD11B1 (0.50) ADORA1ADORA2AMPLALOX5APFEN1
SCHEMBL2303486 0.72 MPL (0.37) POLBMPLALOX5APFEN1
SCHEMBL2386527 0.71 ADORA2A (0.43) ADORA2AALDH1A1KDM4EMPLLMNA
SCHEMBL1891048 0.70 FEN1 (0.49) MAP2K4ADORA1ADORA2AMPLALOX5AP
SCHEMBL1655716 0.70 ADORA2A (0.48) ADORA1ADORA2AKDM4EPOLBMPL
SCHEMBL2386650 0.69 MPL (0.41) ADORA1ADORA2AALDH1A1MPLCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105543-A1 NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2011-05-05 US claimed
US-20110105543-A1 NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2011-05-05 US disclosed
EP-2262767-A1 NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NeuroSearch A/S (DK) 2010-12-22 EP disclosed
WO-2009112461-A1 NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105543-A1 NOVEL TRIARYL DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS CHRNA5, CHRNA3, CHRM3 MAP2K4 816/4885CLK1 2310/4885DYRK1A 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.